PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
NN Shaha, PL Zinzanib,c, TA Eyred, K Izutsue, AJ Alencarf, K Patelg, T Munirh, DE Tsaii, ML Wangj, LYGN Presenterk
a Medical College of Wisconsin, Milwaukee, United States
b IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia Seràgnoli, Italy
c Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
d Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
e Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
f Sylvester Comprehensive Cancer Center, Miami, United States
g Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, United States
h Department of Haematology, St. James's University Hospital, Leeds, United Kingdom
i Loxo@Lilly, Indianapolis, United States
j MD Anderson Cancer Center, Houston, United States
k Eli Lilly and Company, Brazil
Ver másLido
293
Vezesque se leu este artigo
146
Total PDF
147
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Maio | 18 | 16 | 34 |
| 2024 Abril | 47 | 14 | 61 |
| 2024 Março | 25 | 26 | 51 |
| 2024 Fevereiro | 15 | 27 | 42 |
| 2024 Janeiro | 15 | 15 | 30 |
| 2023 Dezembro | 10 | 23 | 33 |
| 2023 Novembro | 12 | 16 | 28 |
| 2023 Outubro | 5 | 9 | 14 |
